Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of therapeutic HIV vaccine LFnp24B.C with ART in HIV-1 infection
ChiCTR2100042293Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LFn-p24B.C in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Safety profile, Occurrence of HIV RNA rebound after analytical treatment interruption and 2 more. Started Sep 2020; status: recruiting.
02
Drugs
LFn-p24B.C
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2100042293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042293.